Table 3.

GATA3 single nucleotide polymorphisms and breast cancer outcomes among patients in the treated group by tamoxifen therapy in S8897 trial

Genotype	Tamoxifen Treated Group (n=220)			No Tamoxifen Treated Group (n=221)
	# events/patients	Adjusted HR (95% CI)	Adjusted P	# events/patients	Adjusted HR (95% CI)	Adjusted P
A. Overall survival
rs3802604
AA	14/78	1.00		17/85	1.00
GA	19/105	1.09 (0.54-2.20)	0.82	31/100	1.56 (0.86-2.81)	0.14
GG	17/35	2.66 (1.31-5.43)	0.007	13/35	2.23 (1.08-4.60)	0.03
Per risk allele		1.66 (1.13-2.44)	0.009		1.50 (1.05-2.14)	0.03
rs568727
CC	13/76	1.00		14/82	1.00
AC	19/105	1.02 (0.50-2.06)	0.96	33/99	1.97 (1.05-3.71)	0.04
AA	18/37	2.89 (1.40-5.96)	0.004	14/40	2.28 (1.08-4.80)	0.03
Per risk allele		1.71 (1.15-2.54)	0.008		1.51 (1.07-2.14)	0.02
B. Disease-free survival
rs3802604
AA	21/78	1.00		28/85	1.00
GA	27/105	0.95 (0.53-1.70)	0.87	38/100	1.16 (0.71-1.89)	0.56
GG	22/35	2.59 (1.41-4.73)	0.002	15/35	1.53 (0.81-2.87)	0.19
Per risk allele		1.62 (1.16-2.26)	0.005		1.22 (0.90-1.67)	0.2
rs568727
CC	20/76	1.00		24/82	1.00
AC	28/105	0.98 (0.55-1.74)	0.94	40/99	1.43 (0.86-2.39)	0.17
AA	22/37	2.60 (1.41-4.82)	0.002	17/40	1.65 (0.88-3.07)	0.12
Per risk allele		1.60 (1.14-2.24)	0.007		1.29 (0.96-1.75)	0.09

Footnote: Hazard ratios (HRs), 95% confidence intervals (CIs) and p-values were derived from Cox hazard regression models with adjustment for age at enrollment, race and ethnicity, and treatment arms. Estimates of per risk allele were derived from an additive genetic model by treating genotypes as 0, 1 and 2 according to the copy number of risk allele. P-values ≤ 0.001 were considered statistically significant to account for multiple testing for 12 genetic variants in GATA3.